Stockreport

Annexon: Unforced Error Sullies Prospects [Seeking Alpha]

Annexon, Inc. - common stock  (ANNX) 
PDF ANX005 has the potential to become the first FDA approved therapy for Guillain-Barré syndrome (GBS). GBS is a rare disease that affects patients in different ways. [Read more]